Etudes cliniques en cours

Découvrez ici la liste des différentes études cliniques en cours classées par centre.

CHU Liège

  • Neodjuvant/adjuvant
    NSCLC resectable Iib/IIIa
    Platinum doublet chemotherapy ± pembrolizumab
  • 1-2LM
    NSCLC Squameux/non-squameux
    • Cisplatine/gemcytabine + CAN 04
    • CAN04 seul
    Slots variables
    GCT1021 -01
    Slots variables
    PDR001 + NIR178
  • adjuvant
    Atezolizumab + vaccin personnalisé
    Slots variables
    Pivot 02
    Nektar-IL2 + nivo Q3W

CHU Mont-Godinne

Etudes sponsorisées interventionnelles en cours:

  • PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
  • Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.

Etudes sponsorisées non interventionnelles en cours:

  • BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.

Etudes académiques non interventionnelles en cours:

  • ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.

Cliniques Universitaires Saint-Luc

Etudes Onco en cours
1st line
BO29554 study (B-FAST)A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)NSCLC (ROS+) A venir: BRAF V600+P.C
ADRIATIC (D933QC00001)Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)SCLC limités post-chimioradioT.P
ANAM 17-21A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLCNSCLC cachexiaT.P
Zenith20 (Spectrum) (SPI-POZ-202)Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)NSCLC IV EGFR ou HER2 exon 20 inser/mutT.P
CA209-73LA Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC)NSCLC IIIA/B/CTP
2nd line
ImmunoSABRPhase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer NSCLC IVX.G
AMG510 (20190009)A Phase 3 Multicenter, Randomized, Open
Label, Active-controlled, Study of AMG 510
Versus Docetaxel for the Treatment of Previously
Treated Locally Advanced and Unresectable or
Metastatic NSCLC Subjects With Mutated KRAS
3rd line
ImmunoSABRPhase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer NSCLC IVX.G
EORTC: E2-Radiate 1811E²-RADIatE:
EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
Tous cancers oligométa traités par RthXG
PACIFIC R D4194R00005First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapyNSCLC stage III with durvalumab post chimioradioT.P
Immuno PoumonEtude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumonNSCLC FAb
SPECTAScreening Cancer Patients for Efficient Clinical Trial AccessNSCLC IV naïfs/ thymomes, mésothéliome IV naïfsT.P


Numéro InterneEtudesCodeEudractPathologieTitreMoléculePhaseStatutPI
2018-ONCOHEMA-0228ANAM-17-21ANAM-17-212018-002927-40Non à petites cellules (NSCLC)A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated
weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
Anamorelin HCLPhase 3On hold (Covid)Colinet Benoît
2018-ONCOHEMA-0159PDC-Lung-101PDC-Lung-1012018-002382-19Non à petites cellules (NSCLC)An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) PDC*lung01Phase 1
Phase 2
Ouverte à l'inclusionColinet Benoît
2019-ONCOHEMA-0131CodeBreak 20020190009 2019‐003582‐18Non à petites cellules (NSCLC)A phase 3 multicenter, randomized, open label, active-controlled, study of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with KRAS p.G12C mutationAMG 510Phase 3Ouverte à l'inclusionColinet Benoît
2019-ONCOHEMA-0111PACIFIC-4D9103C000012018-002572-41Non à petites cellules (NSCLC)A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)DurvalumabPhase 3Ouverte à l'inclusionColinet Benoît
2019-ONCOHEMA-0047DRIIV-1OX2016-203-01 2017-000088-34Toutes tumeursAn Open-label, Dose-escalation Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of AsiDNA, a DNA Repair Inhibitor Administered Intravenously, as Single Agent and to Assess the Safety and the Efficacy of AsiDNA in Combination With Carboplatin With or Without Paclitaxel, in Patients With Advanced Solid TumorsAsiDNAPhase 1bOuverte à l'inclusionCanon Jean-Luc
2019-ONCOHEMA-0035Precision 2 - Afatinib1200.2642016-003411-34 Toutes tumeurs (HER2 mut
HER3 mut, EGFR mut
excluding non-squamous nsclc)
Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation followed by the addition of paclitaxel to afatinib at disease progression.AfatinibPhase 2Ouverte à l'inclusionCanon Jean-Luc
2019-ONCOHEMA-0093Precision 2 – Olaparib 1-2018 BSMO2018-002966-37 Toutes tumeurs (specific pathogenic genetic alteration (with the exception of BRCA1/2 mutated breast, prostate and pancreatic cancer and HRD ovarian cancer ))Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.
Olaparib Phase 2Ouverte à l'inclusionCanon Jean-Luc
2018-ONCOHEMA-0205TranslateA9001502Toutes tumeursTreatment resistance following anti-cancer therapiesProspective - Collection d'échantillonsOuverte à l'inclusionCanon Jean-Luc
2018-ONCOHEMA-0173TumorbaseONCOGHDC2017-01Toutes tumeursProspective collection of biological samples for translational research on patients with tumoral or hematological diseases (TUMOR-base)Prospective-Collection d'échantillonsOuverte à l'inclusionCarrasco Javier
2018-ONCOHEMA-00780115101151Non à petites cellules (NSCLC)
Petites cellules (SCLC)
Cardiovascular morbidities and lung cancer treatment: a prospective registryObservationnelleOuverte à l'inclusionColinet Benoît
2018-ONCOHEMA-0216Pacific RD4194R00005Non à petites cellules (NSCLC)First real-world data study on Unresectable stage III NSCLC Patients treated with durvalumab within the Early Access Program (EAP) after chemoradiotherapyDurvalumabObservationnelleOuverte à l'inclusionColinet Benoît
2019-ONCOHEMA-0137EXCLAIM-2TAK-788-30012019-001845-42Non à petites cellules (NSCLC)Phase III clinical trial evaluating TAK-788 versus platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) as first-line treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
TAK-788 Phase 3Ouverture prochaineColinet Benoît
2020-ONCOHEMA-0014Skyscraper 3GO418542019-0044773-29Non à petites cellules (NSCLC)A phase I/III, randomized, double-blind, placebo-controlled study of atezolizumab and tiragolumab compared with durvalumab in patients with unresectable stage III non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiationTiragolumabPhase 1/2/3Ouverture prochaineColinet Benoît


Connectez-vous pour avoir accès au contenu privé.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.